Patients with an aggressive form of lung cancer are set to benefit from a new immunotherapy after NICE recommended durvalumab (Imfinzi) for use on the NHS in England.
In final draft guidance published today, NICE has approved durvalumab for adults with limited-stage small cell lung cancer – a form of the disease where the cancer is confined to one side of the chest and has not progressed following initial chemotherapy and/or radiotherapy.
SCLC is a fast-growing and aggressive cancer, with limited treatment options and poor survival rates. Until now, there have been no maintenance treatments available for patients whose cancer had not progressed after chemoradiotherapy.
Durvalumab, developed by AstraZeneca, is administered via infusion every 2–4 weeks and works by helping the immune system target and destroy cancer cells.
This represents a significant improvement in survival outcomes, offering new hope to the estimated 530 patients in England who could benefit from the treatment each year.
Helen Knight, Director of Medicines Evaluation at NICE, commented:
“I am very pleased we have been able to recommend this effective new treatment for a highly aggressive form of lung cancer with limited treatment options.
“This is a devastating disease with a poor prognosis, so a drug proven to improve the length and quality of people’s lives, giving them more precious time with their family and friends, is most welcome.
“This is the first immunotherapy NICE has recommended for limited-stage small cell lung cancer, and we are determined to ensure we continue focusing on what matters most by getting the best care to people fast.”
Durvalumab is now available on the NHS for eligible patients, marking the first major advance in limited-stage SCLC treatment in over 20 years. It is expected to improve quality of life and extend survival for those living with this challenging condition.
Image credit: iStock
